Results 301 to 310 of about 2,034,935 (392)

Risk of Secondary Immune Thrombocytopenia following Alemtuzumab Treatment for Multiple Sclerosis: A Systematic Review and Meta-analysis [PDF]

Yuying Sun, Zhimei Liu, Jianguo Yang, Qingqing Jia, Jinglong Sun, Lei Wang, Fengjiao Liang, Shiyuan Song, Kaixi Wang, Xia Zhou   +9 more
openalex   +1 more source

Immune thrombocytopenia

Japanese Journal of Thrombosis and Hemostasis, 2018
openaire   +2 more sources

Acute collapse in a dog with multiple autoimmune syndromes and polymyositis complicated by suspected organophosphate/carbamate toxicity

Veterinary Record Case Reports, Volume 14, Issue 1, February 2026.
Abstract A 6.5‐year‐old, spayed, female dog presented in acute respiratory distress. On admission, the dog exhibited dyspnoea, bradycardia, cyanosis and gastrointestinal signs, requiring immediate intubation and mechanical ventilation. Diagnostic evaluation revealed reduced butyrylcholinesterase activity, non‐cardiogenic pulmonary oedema, elevated ...
Sarah Hefer, Efrat Kelmer, Michal Mazaki Tovi, Dana Peery, Kobi Aharoni, Nir Edry, Sigal Klainbart   +6 more
wiley   +1 more source

Ubiquitous dysregulation of the Wnt pathway in immune thrombocytopenia genetic susceptibility. [PDF]

Blood Vessel Thromb Hemost
Lecluze E, Da Silva Faria S, Saby M, Yu J, Lisi V, Lavallée VP, Kim TO, Scheurer ME, Grimes AB, Pincez T.   +9 more
europepmc   +1 more source

Thromboelastography variables, immune markers, and endothelial factors associated with shock and NPMODS in children with severe sepsis [PDF]

, 2019
Ignell, Steven P, Lin, John C, Saini, Arun, Spinella, Philip C   +3 more
core   +1 more source

Low ICU Admission and Excellent Outcomes in MIS‐C: A Swedish Study From an Open Society

Acta Paediatrica, Volume 115, Issue 2, Page 335-344, February 2026.
ABSTRACT Aim During the COVID‐19 pandemic, Sweden chose a more open public health approach. A general concern was that this approach would affect the population negatively. We describe the Swedish national MIS‐C cohort and risk factors for severe disease defined as admission to the intensive care unit and cardiogenic shock.
Petra Król, Maria Altman, Stefan Berg, Lillemor Berntson, Petter Brodin, Anders Fasth, Robin Kahn, Jenny Lingman Framme, Maria Mossberg, Charlotta Nordenhäll, Karin Palmblad, André Rudolph, Eva Säve‐Söderbergh, AnnaCarin Horne   +13 more
wiley   +1 more source

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers

European Journal of Haematology, Volume 116, Issue 2, Page 174-184, February 2026.
ABSTRACT BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non‐trial settings. We conducted a real‐life study in secondary and tertiary cancer centers to evaluate the PFS in 18–59 years aged ...
Marco Picardi, Annamaria Vincenzi, Claudia Giordano, Novella Pugliese, Alessia Scarpa, Assunta Lombardi, Elena Vigliar, Giancarlo Troncone, Rosaria Cappiello, Massimo Mascolo, Giovanni Esposito, Maria Prastaro, Ciro Santoro, Roberta Esposito, Carlo Gabriele Tocchetti, Ciro Mainolfi, Rosa Fonti, Silvana Del Vecchio, Fabio Trastulli, Mario Annunziata, Rossella Iula, Catello Califano, Marianna Carchia, Marcello Persico, Alessia Salemme, Emanuele Nicolai, Andrea Soricelli, Marco Salvatore, Fabrizio Pane   +28 more
wiley   +1 more source

PF703 LONG‐TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM

, 2019
James B. Bussel, Donald M. Arnold, Ralph V. Boccia, Michael Boxer, Nichola Cooper, Quentin A. Hill, Darla Liles, M. Scholzberg, Robert P. Numerof, Hany Zayed, Sandy Tong, Anne‐Marie Duliège   +11 more
openalex   +1 more source

Splenic megakaryocyte density in immune thrombocytopenia: insights from a histologic analysis of splenectomy specimens. [PDF]

Int J Clin Exp Pathol
Koyama K, Tsukita H, Miyabe K, Yoshida M, Kudo-Asabe Y, Umakoshi M, Sageshima M, Yoshioka T, Wakabayashi T, Sato T, Takahashi M, Sasaki T, Sugiyama T, Kitabayashi A, Saito R, Shibata S, Nanjo H, Takahashi N, Arita J, Goto A.   +19 more
europepmc   +1 more source

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source